Prevention effect of orally active heparin conjugate on cancer-associated thrombosis

Taslim A. Al-Hilal, Farzana Alam, Jin Woo Park, Kwangmeyung Kim, Ick Chan Kwon, Gyu Ha Ryu, Youngro Byun

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Thrombogenesis is a major cause of morbidity and mortality in cancer patients. Prophylaxis with low-molecular-weight heparin (LMWH) is recommended for cancer patients, but requires non-parenteral delivery methods for long-term treatments. In this study, we sought to generate a new oligomeric-bile acid conjugate of LMWH that can be used for oral delivery. We first synthesized a tetramer of deoxycholic acid (tetraDOCA), which was site-specifically conjugated at the end saccharide of LMWH. When LMWH-tetraDOCA conjugate (LHe-tetraD) was orally administered at a dose of 5 mg/kg in ICR mice, the maximum anti-factor Xa level was increased up to 0.62 ± 0.05 IU/mL without any evidence of liver toxicity, gastrointestinal damage, or thrombocytopenia. The cancer-associated thrombosis was induced in tumor-bearing mice by local heat application, and the fibrin deposition in tumors was evaluated. The oral administration of LHe-tetraD (either a single dose or multiple daily doses for up to 10 days) in mice substantially abolished the coagulation-dependent tropism of fibrinogen in the heated tumors and significantly decreased hemorrhage, compared to the mice treated with saline or subcutaneous injection of LMWH. Thus, the anticoagulation effect of oral LHe-tetraD invokes the benefits of oral delivery and promises to provide an effective and convenient treatment for cancer patients at risk of thrombosis.

Original languageEnglish
Pages (from-to)155-161
Number of pages7
JournalJournal of Controlled Release
Publication statusPublished - 2014 Dec 10

Bibliographical note

Funding Information:
This study was supported by grants from the Converging Research Center Program (grant no. 2012K-001398 ), ERC program (grant no. 2010-0027955 ), and the Bio & Medical Technology Development Program (grant no. 2012028833 ) through the National Research Foundation of Korea (NRF) funded by Korea government [MSIP], and Mediplex Corp., Korea .

Publisher Copyright:
© 2014 Elsevier B.V. All rights reserved.


  • Anticoagulants
  • Cancer-associated thrombosis
  • Heparin conjugate
  • Oral delivery

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Prevention effect of orally active heparin conjugate on cancer-associated thrombosis'. Together they form a unique fingerprint.

Cite this